Nkarta, Inc. (NASDAQ: NKTX) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $16.00 to $15.00. They now have a "buy" rating on the stock.
Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights [Yahoo! Finance]
Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights
CD70 Antibodies CD70 Targeting Therapies Clinical Trials Market Opportunity Insight [Yahoo! Finance]
Nkarta: Down 50% Since March With A Clinical Catalyst Ahead [Seeking Alpha]